Deciphera Pharma Stock Price, News & Analysis

Deciphera Pharmaceuticals has announced the completion of enrollment in its pivotal Phase 3 MOTION study for vimseltinib, targeting patients with tenosynovial giant cell tumor (TGCT) not suitable for surgery. The company expects to release top-line results in Q4 2023.

Prior Phase 1/2 data indicated vimseltinib's promising clinical activity, with objective response rates at 69% in Phase 1 and 53% in Phase 2 Cohort A. The drug was well-tolerated, showing significant improvements in patient-reported pain and stiffness.

The MOTION study aims to validate vimseltinib's efficacy and safety as a potential best-in-class treatment for TGCT.

Deciphera Pharmaceuticals (NASDAQ: DCPH) announced participation in key investor conferences. Management will engage in fireside chats at the Cowen 43rd Annual Health Care Conference on March 6, 2023, at 2:50 PM ET in New York, and at the Barclays Global Healthcare Conference on March 15, 2023, at 5:00 PM ET in Miami Beach. Both sessions will be webcast live on the company's website, with replays available for 90 days. Deciphera focuses on innovative cancer treatments, notably the approved QINLOCK® for fourth-line GIST, available in major markets including the US, UK, and Australia. For more information, visit www.deciphera.com.

Deciphera Pharmaceuticals (DCPH) reported fourth quarter 2022 total revenue of $36.3 million, including $32.9 million from QINLOCK net product sales, marking a 39% increase year-over-year. Year-end revenue reached $134.0 million, up from $96.1 million in 2021. QINLOCK is now included in China’s National Reimbursement Drug List and has shown strong clinical results, with a median progression-free survival of 14.2 months. The company raised approximately $143.7 million from a public offering, expected to fund operations into 2026. Upcoming milestones include completing enrollment in the MOTION study and initiating the INSIGHT study in 2023.

Deciphera Pharmaceuticals (NASDAQ: DCPH) announced its participation in fireside chats at two upcoming investor conferences. The first event, Guggenheim Healthcare Talks Oncology Day, will be held on February 9, 2023, at 10:45 AM ET in New York, NY. The second, SVB Securities Global Biopharma Conference, is scheduled for February 15, 2023, at 3:00 PM ET and will be virtual. Both events will be webcast live, with recordings available for 90 days afterward. Deciphera is focused on developing innovative cancer treatments, including QINLOCK®, approved in multiple countries for fourth-line GIST treatment.

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) announced that it will release its fourth quarter and full year 2022 financial results on February 7, 2023. A live conference call and webcast will take place at 8:00 AM ET on the same day to discuss the results and provide a corporate update. The call will be accessible via a link on their website, with a replay available for 30 days after the event. Deciphera focuses on developing innovative cancer medicines, leveraging its kinase inhibitor platform, and has multiple clinical studies in progress, including the approved drug QINLOCK® for fourth-line GIST treatment.

Deciphera Pharmaceuticals (NASDAQ: DCPH) has successfully closed its public offering of 7,986,111 shares of common stock at $18.00 per share, generating approximately $143.7 million in gross proceeds. The offering included 1,041,666 shares granted to underwriters under their full exercise option. The net proceeds will support Deciphera's Phase 3 INSIGHT study of QINLOCK in GIST patients, advances in vimseltinib and DCC-3116 developments, as well as general operating expenses. J.P. Morgan, Jefferies, Cowen, and Guggenheim Securities managed the offering. This press release contains forward-looking statements related to the use of proceeds and associated risks.

Deciphera Pharmaceuticals has presented data from the INTRIGUE Phase 3 clinical study of QINLOCK^® for second-line treatment of gastrointestinal stromal tumor (GIST) patients. The research indicates that patients with certain KIT mutations experienced significant benefits with QINLOCK, achieving a median progression-free survival (mPFS) of 14.2 months, compared to 1.5 months for sunitinib. QINLOCK also demonstrated an objective response rate of 44.4% versus 0% for sunitinib. The company plans to initiate the INSIGHT pivotal Phase 3 study in the second half of 2023, further exploring QINLOCK's potential as a standard-of-care treatment for this patient demographic.

Deciphera Pharmaceuticals (NASDAQ: DCPH) announced an underwritten public offering of 6,944,445 shares of common stock at $18.00 per share, aiming to raise approximately $125 million before expenses. This offering includes a 30-day option for underwriters to purchase an additional 1,041,666 shares. The funds will support Deciphera's Phase 3 INSIGHT study of QINLOCK, the development of vimseltinib, and DCC-3116, among other R&D initiatives. The offering is expected to close on January 24, 2023, subject to customary conditions. J.P. Morgan, Jefferies, Cowen, and Guggenheim Securities are managing the offering.

Deciphera Pharmaceuticals (NASDAQ: DCPH) announced its intention to offer and sell $125 million of its common stock in an underwritten public offering, with a potential additional $18.75 million if underwriters exercise their option. Proceeds will fund the planned Phase 3 INSIGHT study of QINLOCK® and the development of vimseltinib and DCC-3116, among other uses.

The offering is subject to market conditions, and there are no assurances regarding completion or terms. J.P. Morgan, Jefferies, Cowen, and Guggenheim are managing the offering. The securities are being offered under an effective shelf registration statement.